MSB Trading 2021 - paradigm shift, page-362

@otherperspective and posters such as yourself @ddwn who have been working to counter the narrative of the shorters on this forum. (Another word in this case for narrative is tripe)
To all shareholders who support the rational data led analysis on the long term prospects of Mesoblast, we can celebrate that the data shows that these prospects are even brighter. The genie of success is well and truly out of the Mesolamp and unfortunately for the shorters it is not going back. What the next 3 years is going to tell us is how many of our wishes it is going to grant. Given the dire consequences of the current situation, lets hope the first is srGvHD, accelerated approval for use by children.
I have no more money to invest, but IMO if I wanted to diversify away from Mesoblast, a few quid on Novartis shares might be the order of the day. Rumour has it, that have the inside track on a blockbuster new therapy. If I find out what it is, please rest assured I will report it here first!
regards to all shareholders
Yelrom
reply to @ddwn post